Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491311 | 1.00 | CASP3 (0.50) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL5496674 | 1.00 | CASP3 (0.50) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL26172641 | 0.89 | CPB1 (0.55) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL26172649 | 0.89 | CPB1 (0.55) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL26172642 | 0.89 | CPB1 (0.55) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL30481174 | 0.89 | CPB1 (0.55) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL14288630 | 0.84 | NAAA (0.55) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL14288653 | 0.82 | CTSK (0.53) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL7404163 | 0.81 | CASP1 (0.52) | CASP3CASP1CPB1NAAACASP7 | |
| SCHEMBL645015 | 0.81 | CASP3 (0.42) | CASP3CASP1CPB1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| CN-1525978-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | 伊邓药品公司 | 2004-09-01 | — | — | CN | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | CASP3 1/4885CASP1 4/4885CPB1 54/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | CASP3 1/4885CASP1 6/4885CPB1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.